[HTML][HTML] PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
F Janku, JJ Wheler, SN Westin, SL Moulder… - Journal of clinical …, 2012 - ncbi.nlm.nih.gov
Journal of clinical oncology, 2012•ncbi.nlm.nih.gov
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring
PIK3CA Mutations - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI
Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text Archive
Search in PMC Advanced Search User Guide Journal List J Clin Oncol PMC3295566 Other
Formats PDF (345K) Actions Cite Collections Share Permalink Copy RESOURCES Similar
articles Cited by other articles Links to NCBI Databases Journal List J Clin Oncol PMC3295566 …
PIK3CA Mutations - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI
Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text Archive
Search in PMC Advanced Search User Guide Journal List J Clin Oncol PMC3295566 Other
Formats PDF (345K) Actions Cite Collections Share Permalink Copy RESOURCES Similar
articles Cited by other articles Links to NCBI Databases Journal List J Clin Oncol PMC3295566 …
Abstract
Purpose
Mutations of the PIK3CA gene may predict response to phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) inhibitors. Concomitant mutations in the mitogen-activated protein kinase (MAPK) pathway may mediate resistance.
ncbi.nlm.nih.gov
